Aker BP Q1 Profit Jumps on Higher Oil Prices and Asset Reversal 
Trump Invites Top CEOs Including Nvidia, Apple, Boeing to China Summit With Xi Jinping 
AWS Data Center Overheating Disrupts Cloud Services in Northern Virginia 
Rivian Hints at New R2 Variants as Production Ramps Up Ahead of 2027 Launch 
Continental AG Shares Jump After Q1 Profit Beats Expectations 
Strategy Reports Q1 Loss as Bitcoin Holdings Trigger $14.46 Billion Unrealized Hit 
Agentic AI Boom to Drive Massive Growth in CPU Market, UBS Says 
BHP Attracts AI-Focused Investors as Copper Demand Surges 
Novo Nordisk Raises 2026 Outlook on Strong Wegovy Demand 
Samsung Surpasses $1 Trillion Market Cap Amid AI Chip Boom and Apple Partnership Talks 
Orsted Q1 EBITDA Beats Expectations Despite U.S. Impairments 
Shell Q1 Profit Surges to Two-Year High as Dividend Rises Despite War-Driven Debt Pressure 
Lufthansa Q1 Loss Narrows as Strong Summer Travel Demand Boosts Outlook 
Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift 
Supermicro Forecasts Strong Q4 Revenue Growth as AI Server Demand Surges 
Hua Hong Semiconductor Stock Surges to Multi-Year High Amid AI Boom 
OCBC Q1 Profit Rises 5% on Strong Wealth Management and Non-Interest Income 
EMERYVILLE, Calif., April 26, 2018 -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the company will report first quarter 2018 financial results on Thursday, May 3, 2018, after market close. Subsequently, Adamas’ management team will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the financial results and provide a corporate update.
Investor Conference Call and Webcast
The conference call can be accessed by dialing 844-215-3280 for participants in the U.S. or Canada and 484-747-6383 for international callers. The webcast can be accessed live via the investor section of the Adamas website at http://ir.adamaspharma.com/events-presentations and will be available for replay until June 3, 2018.
About Adamas Pharmaceuticals, Inc.
Adamas’ goal is to create and commercialize a new generation of medicines intended to lessen the burden of chronic neurologic diseases on patients, caregivers and society using its deep understanding of time-dependent biology. The company is focused on the commercial launch of GOCOVRI™ (amantadine) extended release capsules (previously ADS-5102), the first and only medicine approved by the U.S. Food and Drug Administration for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications, and delivering on its pipeline of differentiated investigational programs. Those programs include: ADS-5102 in development for the treatment of multiple sclerosis walking impairment; and ADS-4101, a high-dose, modified release lacosamide in development for the treatment of partial onset seizures in patients with epilepsy. For more information about Adamas and its unique approach to developing medicines based on time-dependent biology, please visit www.adamaspharma.com.
Contact: Ashleigh Barreto Director, Corporate Communications & Investor Relations Adamas Pharmaceuticals, Inc. 510-450-3567 [email protected]
